Results 181 to 190 of about 1,981,418 (307)

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source

Systemic and Phloem-Specific Protein Targeting by High Affinity Nanobodies Expressed From a Plant RNA Virus Vector. [PDF]

Mol Plant Pathol
Chen AYS, Spigolon G, Scipioni L, Ng JCK.   +3 more
europepmc   +1 more source

Protein Targeting to Glycogen (PTG): A Promising Player in Glucose and Lipid Metabolism. [PDF]

Biomolecules, 2022
Deng X, Wang C, Xia Y, Yuan G.
europepmc   +1 more source

Protein targeting in yeast [PDF]

Journal of General Microbiology, 1991
openaire   +2 more sources

Screening for lung cancer: A systematic review of overdiagnosis and its implications

Molecular Oncology, EarlyView.
Low‐dose computed tomography (CT) screening for lung cancer may increase overdiagnosis compared to no screening, though the risk is likely low versus chest X‐ray. Our review of 8 trials (84 660 participants) shows added costs. Further research with strict adherence to modern nodule management strategies may help determine the extent to which ...
Fiorella Karina Fernández‐Sáenz, Laura de la Torre‐Perez, David R Baldwin, Carlijn van der Aalst, Mangesh Thorat, David Ritchie, Andre L Carvalho, Carolina Espina, Ivan Solà, Carlos Canelo‐Aybar, Moira Magdalena Pissinis, Pablo Alonso‐Coello, Ana Carolina Pereira Nunes Pinto   +12 more
wiley   +1 more source

Multivalent fusion protein targeting VEGFR2 and DR5 receptors: assessing the antiangiogenic and antitumor effects via multimodal microangiography. [PDF]

J Transl Med
Druzhkova IN, Orlova AG, Fedulova AS, Avakiants AV, Isakova AA, Kukovyakina EV, Zijian Y, Plotnikova EA, Trunova GV, Pankratov AA, Plekhanov AA, Kurnikov AA, Subochev PV, Shaytan AK, Gasparian ME, Kirpichnikov MP, Dolgikh DA, Razansky D, Yagolovich AV.   +18 more
europepmc   +1 more source

RecF protein targeting to post-replication (daughter strand) gaps II: RecF interaction with replisomes. [PDF]

Nucleic Acids Res, 2023
Henry C, Kaur G, Cherry ME, Henrikus SS, Bonde NJ, Sharma N, Beyer HA, Wood EA, Chitteni-Pattu S, van Oijen AM, Robinson A, Cox MM.   +11 more
europepmc   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Get4/5-mediated remodeling of Get3's substrate-binding chamber: Insights into tail-anchored protein targeting by the GET pathway. [PDF]

J Biol Chem
Granados-Villanueva D, Rossow A, Kim KH.
europepmc   +1 more source

Fibroblast Activation Protein-Targeting Minibody-IRDye700DX for Ablation of the Cancer-Associated Fibroblast with Photodynamic Therapy. [PDF]

Cells, 2023
Smeets EMM, Dorst DN, Franssen GM, van Essen MS, Frielink C, Stommel MWJ, Trajkovic-Arsic M, Cheung PF, Siveke JT, Wilson I, Mascioni A, Aarntzen EHJG, van Lith SAM.   +12 more
europepmc   +1 more source